MMP inhibition as a potential therapeutic strategy for CHF

Congestive heart failure (CHF) is a leading cause of death in developed countries and its prevalence is increasing throughout the world. Progressive left ventricular dilation and contractile dysfunction cause most cases of CHF. Recent therapies have targeted the neurohumoral system, with few therapies directed toward the actual dilation process; however, emerging data indicate that certain members of the family of metalloenzymes, the matrix metalloproteinases, are not only associated with ventricular dilation, but may actually mediate the dilation process. Because these enzymes are extracellular and are pharmacologic targets, matrix metalloproteinase inhibition is a novel potential therapy for delaying or preventing heart failure.